news TALEN is a more efficient gene editing tool for tightly packed DNA, finds study 28 January 2021 | By Hannah Balfour (Drug Target Review) TALEN was shown to be almost five times more efficient than CRISPR-Cas9 at locating and editing genes in heterochromatin.
news Mavoglurant could improve eye gaze in fragile X patients 25 January 2019 | By Iqra Farooq (Drug Target Review) A first stage trial involving the experimental drug mavoglurant has shown early success in the treatment of gaze avoidance in fragile X syndrome patients...
news Class of neurological disorders share 3D genome folding pattern 19 September 2018 | By Drug Target Review Researchers have found another common thread linking nearly all of the TNR expansion diseases...